Modality
Bispecific Ab
MOA
CD3xCD20
Target
KRASG12C
Pathway
Sphingolipid
FLAML
Development Pipeline
Preclinical
~Sep 2012
→ ~Dec 2013
Phase 1
~Mar 2014
→ ~Jun 2015
Phase 2
~Sep 2015
→ ~Dec 2016
Phase 3
~Mar 2017
→ ~Jun 2018
NDA/BLA
~Sep 2018
→ ~Dec 2019
Approved
Mar 2020
→ Nov 2030
ApprovedCurrent
NCT03442292
2,562 pts·AML
2022-07→TBD·Recruiting
NCT08913061
28 pts·FL
2020-03→2030-11·Recruiting
2,590 total pts2 indications
CompletedCurrentUpcoming
Catalysts (1)
2030-11-164.6y awayPh3 Readout· FL
Trial Timeline
2020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
Approved
Recruit…
Approved
Recruit…
Catalysts
Ph3 Readout
2030-11-16 · 4.6y away
FL
Recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03442292 | Approved | AML | Recruiting | 2562 | DOR |
| NCT08913061 | Approved | FL | Recruiting | 28 | VA |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-179 | Johnson & Johnson | Approved | KRASG12C | |
| LLY-1184 | Eli Lilly | NDA/BLA | C5 | |
| Zanuderotide | Novartis | Phase 1/2 | VEGF | |
| BMY-4586 | Bristol-Myers Squibb | Preclinical | KRASG12C | |
| Doxarapivir | Bristol-Myers Squibb | Phase 3 | KRASG12C | |
| NVO-1361 | Novo Nordisk | Phase 3 | CD38 | |
| Zorizanubrutinib | Novo Nordisk | Phase 1 | BTK | |
| Pexamavacamten | Daiichi Sankyo | NDA/BLA | TIGIT | |
| AMG-4531 | Amgen | Phase 2/3 | KRASG12C | |
| REG-8074 | Regeneron | Phase 2/3 | KRASG12C |